Abstract. This article reviews current topics in neuroleptic-induced extrapyramidal symptoms in Japan, focusing especially on the clinical features of akathisia and dystonia. Akathisia is a common side effect associated with antipsychotic drugs. It is most commonly characterized by subjective inner restlessness and objective motor signs, especially in the lower extremities. The mechanisms underlying akathisia remain unclear and controversial; however, an increase in the activity of (3-adrenergic systems relative to dopaminergic systems has been hypothesized, based on clinical therapeutic observations that p-blocking agents are effective in this condition. A Japanese version of the Barnes Akathisia Scale has recently been established and uses a standardized videotape method for its precise evaluation. Various acute and chronic manifestations of neuroleptic-induced dystonia have been reported in Japan, including blepharospasm, difficulty in opening the eye lids, torticollis, retrocollis, oculogyric crisis, and Pisa syndrome. This review also introduces several other topics related to drug-induced extrapyramidal symptoms in Japan. These include; 1) the Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), which has recently been established, 2) studies on the discontinuation of anticholinergic drugs, and 3) a summary of extrapyramidal symptoms induced by drugs other than neuroleptics. (Keio J Med 45 (2): 95-99, June 1996) 
Introduction
Forty years have passed since neuroleptics were intro duced into Japan in 1955. During these four decades, the treatment of psychiatric illnesses with these drugs has contributed considerably not only to the remission of the disease itself but to the facilitation of social rehabilitation in psychiatric patients. However, these drugs have not always been beneficial to psychiatric patients; some patients have not responded well to neuroleptics, and others have suffered from uncomfortable side effects such as extrapyramidal symptoms even at recommended therapeutic dosages. These symptoms include parkinson ism, dystonia, akathisia, and tardive dyskinesia (Fig 1) . 1 The present reivew describes current topics in neuroleptic induced extrapyramidal symptoms in Japan, focusing especially on the clinical features of akathisia and dystonia. the Barnes Akathisia Scale, has recently been translated into Japanese and the reliability of its Japanese version has been established.
Generalized kappa values for inter-rater reliability among eight trained raters were found to be higher than 0.68 for all items, and Cohen's kappa values for test-retest reliability when performed by 2 trained raters were higher than 0.88 for all items. In the course of this process, the importance of training raters prior to clinical evaluation and the usefulness of a standardized videotape method in their training were confirmed in this study. This scale has been used in the phase II and phase III placebo-controlled double-blind studies of carteolol in the treatment of neuroleptic induced akathisia.
Tardive akathisia
Acute akathisia usually responds well to anticholinergic agents. However, these drugs are not generally effective in the late-onset type of this condition, tardive akathisia. The mechanisms underlying tardive akathisia are thought to be different from those of the acute type. and to be similar to those underlying tardive dyskinesia. More than 10 cases have been reported in Japan to date, since our first report of tardive akathisia in 1988.9 In contrast to the disappointing performance of treatment regimens for tardive dyskinesia, tardive akathisia seems to be reversible and a couple of successful treatment regimens for this condition have been reported. 10 Nishikawa et al recommended clonidine therapy together with the dis continuation of anticholinergic drugs as an effective treat ment,11 while Kuniyoshi et al reported that relatively low doses of clonazepam had beneficial effects in patients with tardive akathisia which could not be controlled by anti-parkinsonian drugs.12 Tanaka et al reported a patient with tardive akathisia and oculogyric crisis, in whom diazepam (15mg/day) was effective in relieving both symptoms.13 Dystonia Dystonia is a syndrome involving hypertonicity of the muscles, and is manifested by stiffness, twisting, spasms, contraction, and persistent abnormal muscle positions. It can occur in the tongue, neck, extremities, and trunk. Various manifestations of neuroleptic-induced dystonia have been reported in Japan. These include blepharo spasm, difficulty in opening the eye lids, tongue pro trusion, torticollis, retrocollis, oculogyric crisis, and Pisa syndrome. A number of therapeutic trials for various dystonic manifestations have been reported in the Japanese literature.
Blepharospasm
Fukuzako et al reported 3 patients with tardive dystonia involving blepharospasm.14,15 The symptoms were allevi ated by trihexyphenidyl (12mg/day) in 2, while reduction of the haloperidol dose was effective in the remaining patient.14,15 Mino et al reported that clonidine (0.15mg/ day) was effective in one patient whose dystonic symp toms did not respond to neuroleptic dose reduction (bromperidol 4mg/day to 2mg/day). 16 Difficulty in opening the eye lids Difficulty in opening the eye lids is a rare side effect of neurleptics which often develops together with blepharo spasm. These symptoms have been often discussed in terms of their relationship to neuroleptic-induced Meige's syndrome. Oomagari et al described seven psychiatric patients with difficulty in opening their eye lids induced by neuroleptics.17 Symptoms were transient and dim inished after neuroleptic dose reduction in most cases. The authors considered the pathophysiology of this con dition to be different from that of tardive dyskinesia.
Tanaka et al described a patient who responded dramati cally to diazepam (15mg/day).13
Pisa syndrome Pisa syndrome is a dystonic reaction that appears in association with neuroleptic therapy and is considered to be a subtype of tardive dystonia. Suzuki et al reported a patient with this condition who was successfully treated by changing medication from haloperidol (18mg/day) to pimozide (18mg/day).18
Meige's syndrome Kimura et al reported the case of a schizophrenic mother and daughter who both exhibited Meige's syn drome after neuroleptic therapy, and suggested that genetic factors could be involved in the vulnerability to neuroleptic-induced movement disorders. 19 Trihexy phenidyl was effective in relieving the daughter's symp toms. Clonazepam has also been reported to be effective in a few cases of Meige's syndrome induced by neuro leptics. 20, 21 Tardive dystonia Tardive dystonia is a late-onset neuroleptic-induced movement disorder and its prevalence in Japan has been estimated as 0.5-2.1% in psychiatric patients receiving neuroleptics.22,23 Although the mechanisms underlying tardive dystonia have previously been considered to be similar to those speculated for tardive dyskinesia, it is now widely thought that tardive dystonia is a separate entity rather than a subtype or variant of tardive dys kinesia, due to differences in its manifestation, response to treatment, and epidemiological findings. Although the condition has been considered refractory in most cases,10 dantrolene sodium has been reported effective in several cases.24-26 Koga et al first reported 3 cases of tardive dystonia in Japan,27 which satisfied the criteria proposed by Burke et al. 28 They reported that clonidine had some effect in all these patients. Harada et al sub sequently followed the clinical courses of 44 patients with tardive dystonia and reported that symptoms im proved in 6 of 9 patients who received clonidine.29
Other Topics
Drug-induced extrapyramidal symptoms scale (DIEPSS)
Although the Simpson & Angus extrapyramidal symp toms (EPS) scale30 has been widely used in western countries, it has rarely been used in studies conducted in Japan. Therefore, there is no accumulated EPS data evaluated using this scale. The establishment of a stan dardized rating scale in Japan has been strongly advocated in order to evaluate neuroleptic-induced extrapyramidal symptoms precisely. As a result, the DIEPSS has been designed and its reliability has recently been established.10 DIEPSS consists of eight individual parameters and one global assessment. The individual parameters are; gait, bradykinesia, sialorrhea, muscle rigidity, tremor, akathisia, dystonia and dyskinesia. Although this scale was originally written in English so that international comparisons could be performed easily, an exact Japanese translation is added under each original English sentence for the convenience of Japanese raters. The severity of each item is graded from 0 (normal) to 4 (severe), and each category has clearly defined anchor points.
The degree of severity of extrapyramidal side effects, as well as the antipsychotic effects, has been given greater weight than ever in evaluating the value of new anti psychotic drugs. The DIEPSS has become a standard rating scale for the evaluation of extrapyramidal side effects in Japan, and is being used in several double blind studies of new antipsychotic drugs now being devel oped in Japan ( Table 1 ). The DIEPSS was also used in the clinical study of carteolol in the treatment of neuroleptic-induced akathisia (phase III) and of rolipram in the treatment of tardive dyskinesia (phase II) .
Studies on the discontinuation of anticholinergic drugs
One of the prominent characteristics of psycho pharmacologic strategies in Japan is the fact that the vast majority of patients receive prophylactic anticholinergic drugs. These are usually prescribed in combination with Inada T and Yagi G: Extrapyramidal Symptoms in Japan 
